AR100209A1 - Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos - Google Patents

Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos

Info

Publication number
AR100209A1
AR100209A1 ARP150101268A ARP150101268A AR100209A1 AR 100209 A1 AR100209 A1 AR 100209A1 AR P150101268 A ARP150101268 A AR P150101268A AR P150101268 A ARP150101268 A AR P150101268A AR 100209 A1 AR100209 A1 AR 100209A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
halogen
treatment
substituted
glyt1
Prior art date
Application number
ARP150101268A
Other languages
English (en)
Inventor
Pinard Emmanuel
Winter Michael
Alberati Daniela
Koerner Annette
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR100209A1 publication Critical patent/AR100209A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Son inhibidores de GlyT1, para su uso en el tratamiento de trastornos hematológicos, en particular, para su uso en el tratamiento de enfermedad de células falciformes y talasemia, o para el tratamiento de pacientes con síndromes de sobrecarga de hierro, tales como la hemocromatosis hereditaria. Reivindicación 5: Un inhibidor de GlyT1 de acuerdo con una cualquiera de las reivindicaciones 1 - 4, en el que el inhibidor de GlyT1 se selecciona de un compuesto de fórmula (1) en los que R¹ es halógeno, alquilo inferior sustituido con halógeno, ciano o S(O)₂-alquilo inferior; R² es alquilo inferior, alquilo inferior sustituido con halógeno o es (CH₂)ₒ-cicloalquilo; R³ es alquilo inferior, NH₂ o amino sustituido con uno o dos alquilos inferiores; X C o N; n es 1 ó 2; o es 0, 1 ó 2; así como sales de adición de ácido farmacéuticamente aceptables del mismo; o es un compuesto de fórmula (2) en el que R¹ es halógeno, alquilo inferior, alquilo inferior sustituido con halógeno, alcoxi, ciano o S(O)₂-alquilo inferior; R² es alquilo inferior, alquilo inferior sustituido con halógeno o es (CH₂)ₒ-cicloalquilo; R³ es alquilo inferior, NH₂ o amino sustituido con uno o dos alquilos inferiores; X es C o N; X¹ es C o N; en el que solo uno de X y X¹ es N; n es 1 ó 2; o es 0, 1 ó 2; así como sales de adición de ácido farmacéuticamente aceptables del mismo.
ARP150101268A 2014-04-30 2015-04-28 Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos AR100209A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14166497 2014-04-30

Publications (1)

Publication Number Publication Date
AR100209A1 true AR100209A1 (es) 2016-09-21

Family

ID=50677958

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101268A AR100209A1 (es) 2014-04-30 2015-04-28 Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos

Country Status (18)

Country Link
US (1) US9877963B2 (es)
EP (1) EP3137073B1 (es)
JP (1) JP6283766B2 (es)
KR (1) KR101869185B1 (es)
CN (1) CN106163520B (es)
AR (1) AR100209A1 (es)
CY (1) CY1120508T1 (es)
ES (1) ES2683184T3 (es)
HR (1) HRP20181205T1 (es)
MA (1) MA39927B1 (es)
MY (1) MY189930A (es)
PH (1) PH12016501784A1 (es)
PT (1) PT3137073T (es)
RS (1) RS57535B1 (es)
SG (2) SG10201909382UA (es)
SI (1) SI3137073T1 (es)
TR (1) TR201809598T4 (es)
WO (1) WO2015165842A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3199156A1 (de) * 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika
CU20200106A7 (es) * 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
US11813257B2 (en) 2020-01-09 2023-11-14 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
MX2023010477A (es) * 2021-03-12 2023-11-09 Disc Medicine Inc Composiciones y metodos para tratar la anemia asociada con un trastorno ribosomico.
AU2022273051A1 (en) * 2021-05-14 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
US20240390362A1 (en) * 2021-05-27 2024-11-28 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin
CN119584967A (zh) * 2022-05-31 2025-03-07 迪斯克医药公司 用甘氨酸转运抑制剂治疗肝性卟啉症的组合物和方法
AU2024339974A1 (en) * 2023-09-15 2026-03-26 Disc Medicine, Inc. Glyt-1 inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53252B (sr) * 2003-08-11 2014-08-29 F.Hoffmann-La Roche Ag. Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
DE602006010665D1 (en) * 2005-02-07 2010-01-07 Hoffmann La Roche Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1

Also Published As

Publication number Publication date
WO2015165842A1 (en) 2015-11-05
KR101869185B1 (ko) 2018-06-19
SI3137073T1 (sl) 2018-09-28
CY1120508T1 (el) 2019-07-10
ES2683184T3 (es) 2018-09-25
HRP20181205T1 (hr) 2018-09-21
PH12016501784B1 (en) 2016-11-07
TR201809598T4 (tr) 2018-07-23
EP3137073B1 (en) 2018-06-06
EP3137073A1 (en) 2017-03-08
RS57535B1 (sr) 2018-10-31
JP6283766B2 (ja) 2018-02-21
PT3137073T (pt) 2018-07-27
SG11201608397UA (en) 2016-11-29
CN106163520A (zh) 2016-11-23
MY189930A (en) 2022-03-22
MA39927A (fr) 2017-03-08
MA39927B1 (fr) 2018-09-28
SG10201909382UA (en) 2019-11-28
US20170042888A1 (en) 2017-02-16
KR20160130517A (ko) 2016-11-11
JP2017511385A (ja) 2017-04-20
US9877963B2 (en) 2018-01-30
PH12016501784A1 (en) 2016-11-07
CN106163520B (zh) 2019-12-13

Similar Documents

Publication Publication Date Title
AR100209A1 (es) Inhibidores de glyt1 para su uso en el tratamiento de trastornos hematológicos
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
EA201790202A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
CR20150045A (es) Inhibidores de hepatitis c
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201492281A1 (ru) Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
ECSP13013074A (es) Nuevos derivados de piridina
EA201690989A1 (ru) Ингибиторы syk
DOP2014000016A (es) Indazoles novedosos inhibidores de janus quinasa
CO7350620A2 (es) Nuevos derivados de piridina
CO7350652A2 (es) Piridina-2-amidas útiles como agonistas de cb2
PE20191302A1 (es) Composiciones herbicidas que comprenden acido 4-amino-3-cloro-5-fluoro-6-(4-cloro-2-fluoro-3-metoxifenil) piridina-2-carboxilico o un derivado del mismo y sulfonamidas de triazolopirimidina
CR20150447A (es) Nuevos derivados de pirazol
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
MD20140047A2 (ro) Inhibitori ai protein kinazei
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201592182A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
NI201200192A (es) Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica.
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EA201591195A1 (ru) Новые хинолоновые производные
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201690844A1 (ru) Ингибиторы gsk-3

Legal Events

Date Code Title Description
FC Refusal